E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/3/2018 in the Prospect News Bank Loan Daily.

Alnylam repays $120 million term loan via Bank of America

By Wendy Van Sickle

Columbus, Ohio, Jan. 3 – Alnylam Pharmaceuticals, Inc. repaid its $120 million term loan facility with Bank of America NA on Dec. 27, according to an 8-K filing with the Securities and Exchange Commission.

The term loan, which was scheduled to mature April 29, 2021, was terminated.

Based in Cambridge, Mass., Alnylam is a biopharmaceutical company focused on RNA interference technology.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.